Evidence map›Paper›PMID 40832404›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Pharmacogenomics of steroid-induced ocular hypertension: relationship to high-tension glaucomas and new pathophysiologic insight.

Zeyuan Song, Satyabrata Pany, Shengru Guo, Arpan G Mazumder, Tatsuo Itakura, Jonathan Huang, Evan Magarychoff, Anastasia Gurinovich, Penelope H Benchek, W Daniel Stamer and 12 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Zeyuan SongInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Satyabrata PanyNew England Eye Center, Tufts Medical Center, Boston, MA, USA.
Shengru GuoThe Dr. John T. Macdonald Foundation Department of Human Genetics and the John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.
Arpan G MazumderNew England Eye Center, Tufts Medical Center, Boston, MA, USA.
Tatsuo ItakuraUSC Institute for Genetic Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
Jonathan HuangTufts University Clinical and Translational Science Institute, Boston, MA, USA.
Evan MagarychoffGraduate School of Biomedical Sciences, Tufts University, MA, USA.
Anastasia GurinovichInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Penelope H BenchekDepartment of Population & Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.
W Daniel StamerDepartment of Ophthalmology, Duke University, Durham, North Carolina, USA.
Francis W PricePrice Vision Group, Indianapolis, IN, USA.
Colin E WilloughbyCentre for Genomic Medicine, Biomedical Sciences Research Institute, Ulster University, Northern Ireland, UK.
Srinivasan SenthilkumariDepartment of Ocular Pharmacology, Aravind Medical Research Foundation, Madurai, Tamilnadu, India.
Ronnie J GeorgeMedical Research Foundation, Smt. Jadhavbai Nathamal Singhvee Glaucoma Service, Sankara Nethralaya, Chennai, Tamil Nadu, India.
Srujana ChitipothuCentral Research Instrumentation Facility, Vision Research Foundation, Chennai, Tamil Nadu, India.
Jonathan H LassDepartment of Ophthalmology and Visual Sciences, Case Western Reserve University School of Medicine and University Hospitals Eye Institute, Cleveland, OH, USA.
Sudha K IyengarDepartment of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA.
Stephen G SchwartzBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Naples, FL, USA.
Anthony J GriswoldThe Dr. John T. Macdonald Foundation Department of Human Genetics and the John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0003-1925-7810
Paola SebastianiInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Marianne O PriceCornea Research Foundation of America, Indianapolis, IN, USA.
M Elizabeth FiniNew England Eye Center, Tufts Medical Center, Boston, MA, USA.ORCID 0000-0001-9877-188X

Funding

Tufts Clinical and Translational Science Institute (Clinical Trial Design Labs Supplement)UM1TR004398 · NCATS · TUFTS UNIVERSITY BOSTON · PI Harry P. Selker · 2023 to 2026
$44.5M
TISSUE CULTURE AND HYBRIDOMA MODULEP30EY011373 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI Irina A Pikuleva · 1997 to 2026
$17.7M
Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Victor L Perez · 2004 to 2026
$12.2M
Genetics of Fuchs Corneal DystrophyR01EY016835 · NEI · JOHNS HOPKINS UNIVERSITY · PI GOTTSCH, JOHN D · 2007 to 2017
$5.7M
A Multi-Center Study To Map Genes for Fuchs'DystrophyR01EY016482 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI IYENGAR, SUDHA K · 2005 to 2009
$3.8M
Study of Genetic Basis of Fuchs Corneal DystrophyR01EY016514 · NEI · DUKE UNIVERSITY · PI KLINTWORTH, GORDON KENNETH · 2007 to 2011
$3.1M
METALLOPROTEINASES AND FAILURE TO REEPITHELIALIZER01EY012651 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI FINI, M. ELIZABETH · 1999 to 2006
$2.5M
Discovery Approach to Ocular HypertensionR01EY027315 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI FINI, M ELIZABETH, GAO, XIAOYI RAYMOND · 2017 to 2020
$2.4M
CTSA Predoctoral T32 at Tufts UniversityT32TR004417 · NCATS · TUFTS UNIVERSITY BOSTON · PI DAVID M KENT · 2023 to 2026
$2.2M
Mitochondria and Mustard Damage at the Ocular SurfaceR01EY035220 · NEI · TUFTS MEDICAL CENTER · PI FINI, M ELIZABETH · 2023 to 2025
$1.6M
Integrative Genetic Analyses in Fuchs Endothelial Corneal DystrophyR01EY023196 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI AFSHARI, NATALIE ADEL, IYENGAR, SUDHA K · 2013 to 2015
$1.2M
CWRU Clinical Vision Research InitiativeR21EY015145 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI LASS, JONATHAN H · 2004 to 2008
$750k
NCATS NIH HHS T32 TR004417NCATS NIH HHS UM1 TR004398NEI NIH HHS P30 EY011373NEI NIH HHS P30 EY014801NEI NIH HHS R01 EY012651NEI NIH HHS R01 EY016482NEI NIH HHS R01 EY016514NEI NIH HHS R01 EY016835NEI NIH HHS R01 EY023196NEI NIH HHS R01 EY027315NEI NIH HHS R01 EY035220NEI NIH HHS R21 EY015145Wellcome Trust
6 · The paper itself

Abstract

Adverse drug reactions are a frequent cause of worldwide morbidity and mortality. Glucocorticoids (GCs), commonly used to treat inflammatory diseases, alter gene expression with both beneficial and adverse consequences. When used in the eye, GCs cause steroid-induced ocular hypertension (SIOH) in 30-50% of patients, leading to steroid-induced glaucoma. Evidence suggests that predisposition to SIOH is genetically determined. Here we took a pharmacogenomic approach to discover DNA variants associated with SIOH. We identified 44 SNPs of genome-wide significance (p<5E-08) located at 26 risk loci out of a total of 531 SNPs of suggestive significance (p<5E-06) at 262 risk loci. Unlike SNPs identified in complex disease which are overwhelmingly common in frequency, most SNPs found here were rare or of low frequency, likely discoverable because of their large effect sizes. Follow-up analyses provide insight into the pathogenetic relationship of SIOH to high-tension glaucomas and suggest a new mechanistic paradigm for SIOH pathophysiology.

Indexed as

adverse drug reactiongene expressiongenomic variantglaucomaglucocorticoidsGWASocular hypertensionPharmacogenomicsSNPtranscription

Identifiers

PMID40832404
PMCPMC12363710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.